Cyclacel Limited

Cyclacel Limited is a biotechnology company conducting research in cancer therapeutics.
Cyclacel’s scientific group is headed by Professor David Lane, one of the founders of the field of cell cycle research. The Company’s research programmes are converting insights in cell cycle control into novel treatments for common cancers.
Cyclacel’s world-leading biology is complemented by state-of-the-art rational drug design chemistry.
The product portfolio includes small molecule Cyclin-Dependent Kinase (CDK) inhibitor drugs that regulate the cell cycle (CYC200), novel Penetratin™-drug complexes (CYC300), Pimetic™ drugs mimicking natural cancer suppressing proteins (CYC100), and intelligent targeting and delivery systems for cancer therapeutics using its Penetratin and SGC™ technologies.

Activity:

- Research & Development

Product / Technology type(s) covered:

- Bio
- Drug delivery
- Pharmaceuticals / Therapeutics
- Technology

Therapeutic targets:

- Cancer

Markets Covered

a. HeadQuarter:

b. Continent(s) active:

c. Countries active:

Corporate data:

Number of Employees:

Turnover:

Amount:	Year:	Currency:

Year founded: